A Single Approach to Protein Misfolding Diseases

Company overview

- Founded in 2007, 17 employees, based in Cambridge, MA
- Novel, **breakthrough discovery** targeting multiple toxic **misfolded proteins** with broad applications in aging disorders
- Diseases of aging represent the **world’s largest unmet medical need**
- **NPT088**: highly differentiated drug candidate currently in clinical trials in Alzheimer’s disease
- **Strong drug development and management expertise**
- **Comprehensive IP Portfolio** for novel mechanism, compositions, and therapeutic uses
- **Over $110M in financing raised** to date including a Part the Cloud grant from the Alzheimer’s Association; also received two Michael J. Fox grants awards for Parkinson’s research
- Collaborations with leading institutions: NIH, MGH/Harvard, UCSD, Washington University, Rush University, NYU.
- Part of GE HealthCare Consortium for access to the tau imaging agent $^{18}$F THK-5351.

Unique Platform and Opportunity in Neurodegenerative Diseases

- All misfolded protein aggregates share a targetable “amyloid fold”
- **Proclara simultaneously targets multiple disease-causing misfolded proteins, avoiding single-target limitations of most current approaches**
- Proclara’s General Amyloid Interaction Motif (GAIM)-based molecules bind to and remodel misfolded protein assemblies and facilitate their clearance.
- Another advantage of Proclara’s GAIM-based molecules is that they target plaque specifically and do not interact with monomers.
- Advances in PET imaging for amyloid beta and tau allow early Proof-of-Activity to unlock broader clinical potential.

Pipeline

- **NPT088**: lead candidate Ig fusion protein combining GAIM motif with a portion of human antibody; simultaneously targets amyloid-beta, tau and alpha synuclein (initial indication: Alzheimer’s disease);
  - IND filed end 2015; 6-month dosing Phase 1b study with PET imaging readout for amyloid-beta and tau and cognitive assessment on going with data expected April 2018.
- **NPT189**: back-up candidate Ig fusion protein, targeting systemic amyloidosis diseases, in early preclinical development.
- **GAIM platform**: discovery and development of next generation candidates with improved properties.